Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IOngoingNov 26, 2025POTASSIUM CHLORIDE InjLabeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj...Otsuka ICU Medical LLC · D-0180-2026Class IIOngoingNov 26, 2025Fentanyl citrateCGMP Deviations: Revised interpretation of Acceptable Quality Level (AQL) results.Park Avenue Compounding · D-0178-2026Class IIOngoingNov 26, 2025UltraSure Anti-Perspirant & DeodorantCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0177-2026Class IIOngoingNov 26, 2025San-E-FoamCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0176-2026Class IIOngoingNov 26, 2025Renew Skin Repair CreamCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0175-2026Class IIOngoingNov 26, 2025Renew PeriProtectCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0174-2026Class IIOngoingNov 26, 2025PeriGuard OintmentCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0173-2026Class IIOngoingNov 26, 2025PeriGieneCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0172-2026Class IIOngoingNov 26, 2025McKesson Skin ProtectantCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0171-2026Class IIOngoingNov 26, 2025LantisepticCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0170-2026Class IIOngoingNov 26, 2025LantisepticCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0169-2026Class IIOngoingNov 26, 2025KleenFoam Antimicrobial Foam SoapCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0168-2026Class IIOngoingNov 26, 2025Hand-E-FoamCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0167-2026Class IIOngoingNov 26, 2025GelRite Instant Hand SanitizerCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0166-2026Class IIOngoingNov 26, 2025DermaSarraCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0165-2026Class IIOngoingNov 26, 2025DermaMed OintmentCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0164-2026Class IIOngoingNov 26, 2025DermaKleenCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0163-2026Class IIOngoingNov 26, 2025DermaFungalCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0162-2026Class IIOngoingNov 26, 2025DermaCerinCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0161-2026Class IIOngoingNov 26, 20254-N-1 Skin ProtectantCGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.DermaRite Industries, LLC · D-0160-2026Class IIOngoingNov 26, 2025Bromocriptine Mesylate CapsulesFailed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.Zydus Pharmaceuticals (USA) Inc · D-0159-2026Class IIOngoingNov 26, 2025NIACIN Extended-Release TabletsFailed Dissolution SpecificationsGolden State Medical Supply Inc. · D-0158-2026Class IIIOngoingNov 26, 2025Klarity-C DropsSubpotent DrugImprimis NJOF, LLC · D-0157-2026Class IIIOngoingNov 26, 2025Fesoterodine FumarateFailed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.Alembic Pharmaceuticals Limited · D-0156-2026Class IIOngoingNov 12, 2025Acetaminophen 500mg Caffeine 65mg capletsLabeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch...Aero Healthcare · D-0155-2026Class IIOngoingNov 12, 2025clomiPRAMINE HydrochloridecGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable...Zydus Pharmaceuticals (USA) Inc · D-0154-2026Class IIOngoingNov 12, 2025clomiPRAMINE HydrochloridecGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable...Zydus Pharmaceuticals (USA) Inc · D-0153-2026Class IIOngoingNov 12, 2025clomiPRAMINE HydrochloridecGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable...Zydus Pharmaceuticals (USA) Inc · D-0152-2026Class IIOngoingNov 12, 2025Amoxicillin and Clavulanate Potassium for Oral Suspension USPSubpotent drug; Clavulanate Potassium componentTeva Pharmaceuticals USA, Inc · D-0151-2026Class IIOngoingNov 5, 2025Lisdexamfetamine Dimesylate CapsulesFailed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for...Sun Pharmaceutical Industries Inc · D-0150-2026Class IIOngoingNov 5, 2025Lisdexamfetamine Dimesylate CapsulesFailed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for...Sun Pharmaceutical Industries Inc · D-0149-2026Class IIOngoingNov 5, 2025Lisdexamfetamine Dimesylate CapsulesFailed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for...Sun Pharmaceutical Industries Inc · D-0148-2026Class IIOngoingNov 5, 2025Lisdexamfetamine Dimesylate CapsulesFailed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for...Sun Pharmaceutical Industries Inc · D-0147-2026Class IIOngoingNov 5, 2025Lisdexamfetamine Dimesylate CapsulesFailed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for...Sun Pharmaceutical Industries Inc · D-0146-2026Class IIOngoingNov 5, 2025Lisdexamfetamine Dimesylate CapsulesFailed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for...Sun Pharmaceutical Industries Inc · D-0145-2026Class IIOngoingNov 5, 2025Lisdexamfetamine Dimesylate CapsulesFailed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for...Sun Pharmaceutical Industries Inc · D-0144-2026Class IIOngoingNov 5, 20250.9% SODIUM CHLORIDE InjectionLack of Assurance of Sterility: Potential for flexible container leaks.Otsuka ICU Medical LLC · D-0143-2026Class IIIOngoingNov 5, 2025Everolimus tablets 2.5 mgFailed Impurities/Degradation Specifications: Out of specification for impurity IP-C.Endo USA, Inc. · D-0142-2026Class IIIOngoingNov 5, 2025Everolimus tablets 10 mgFailed Impurities/Degradation Specifications: Out of specification for impurity IP-C.Endo USA, Inc. · D-0141-2026Class IIIOngoingNov 5, 2025Everolimus tablets 7.5mgFailed Impurities/Degradation Specifications: Out of specification for impurity IP-C.Endo USA, Inc. · D-0140-2026

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.